Zepbound: What It Is, How It Works, and What the Trials Actually Show
Zepbound is a weekly injection made by Eli Lilly. The FDA approved it for weight management on November 8, 2023. The active ingredient is tirzepatide. It is the same molecule as Mounjaro but approved for a different purpose.
What Is Zepbound?
Zepbound is a prescription medication for adults with obesity or overweight with at least one weight-related health condition. That includes high blood pressure, high cholesterol, type 2 diabetes, sleep apnea, or heart disease. The FDA approved it specifically for chronic weight management.
The drug is a dual GIP and GLP-1 receptor agonist. GIP stands for glucose-dependent insulinotropic polypeptide. GLP-1 stands for glucagon-like peptide-1. Both are natural hormones your gut releases after eating. Zepbound mimics both at the same time.
This dual action is what separates Zepbound from drugs like Wegovy or Ozempic. Those drugs target only GLP-1. Zepbound hits both receptors. Clinical data shows this combination produces greater weight loss on average.
How Zepbound Works
When tirzepatide activates GLP-1 receptors, it slows digestion and reduces appetite. You feel full faster. You stay full longer. Calorie intake drops without constant willpower.
GIP activation adds two effects. First, it boosts insulin release after meals. Blood sugar rises less after eating. Second, it suppresses glucagon, the hormone that raises blood sugar between meals. Together, the two mechanisms produce a stronger metabolic effect than either alone.
The drug is injected once a week. It has a half-life of about 5 days. You inject it into the abdomen, thigh, or upper arm. Lilly provides single-dose auto-injector pens at each dose level.
Zepbound Dosing Schedule
The standard titration schedule starts low and moves up every 4 weeks. Slower titration means fewer side effects. Your doctor may adjust timing based on how you tolerate each dose.
| Phase | Dose | Duration | Notes |
|---|---|---|---|
| Start | 2.5 mg/week | 4 weeks | Initiation dose only. Not for long-term use at this dose. |
| Step 2 | 5 mg/week | 4+ weeks | First maintenance dose. Some stay here if well tolerated. |
| Step 3 | 7.5 mg/week | 4+ weeks | Optional. Titrate up only if tolerating current dose. |
| Step 4 | 10 mg/week | 4+ weeks | Optional. Common stopping point for many patients. |
| Step 5 | 12.5 mg/week | 4+ weeks | Optional. Approach with caution if side effects increase. |
| Max | 15 mg/week | Ongoing | Maximum approved dose. Used in SURMOUNT-1 for peak results. |
Clinical Trial Results
The SURMOUNT-1 trial enrolled 2,539 adults with obesity or overweight. Participants were not diabetic. The trial ran 72 weeks.
At the 15mg dose, participants lost an average of 20.9% of their body weight. The placebo group lost 3.1%. That is a 17.8 percentage point difference. For a 250-pound person, 20.9% is about 52 pounds.
The SURMOUNT-5 trial compared Zepbound directly to Wegovy (semaglutide 2.4mg). This was the first major head-to-head trial between the two drugs.
Results: Zepbound produced 20.2% average weight loss vs 13.7% on Wegovy over 72 weeks. And 47% of Zepbound patients lost more than 25% of their body weight. Only 27% of Wegovy patients reached that mark. Zepbound won on every primary and secondary endpoint.
Side Effects
The most common side effects are gastrointestinal. They are most intense during dose titration and usually improve as your body adjusts.
- Nausea:Reported in about 30% of patients. Usually worst in the first few weeks of a new dose.
- Diarrhea:About 23% of patients. Often early in titration.
- Vomiting:About 14% of patients. Less common than nausea.
- Constipation:About 11% of patients. Slowed digestion affects bowel regularity.
Most side effects are manageable. Eating smaller meals, avoiding high-fat foods, and staying hydrated all help. If symptoms are severe, your doctor may slow the titration schedule.
Black Box Warning
Important Safety Warning
Zepbound carries a black box warning for thyroid tumors. In animal studies, tirzepatide caused thyroid C-cell tumors. It is unknown whether this applies to humans. Zepbound is contraindicated in patients with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia type 2 (MEN2). Tell your doctor your full family history before starting.
Cost and Insurance Coverage
Zepbound costs approximately $1,060/month without insurance. That is the list price for a 4-week supply of the auto-injector pens.
Many commercial insurance plans cover Zepbound with prior authorization. Your doctor must document your BMI and any qualifying weight-related conditions. Approval rates vary by plan.
Eli Lilly offers a savings card for eligible patients. With commercial insurance and the savings card, out-of-pocket costs can be as low as $550/month. The savings card is not available to Medicare, Medicaid, or government-insured patients.
Compounded tirzepatide from telehealth providers runs $200 to $600/month depending on dose. This is the most common route for people without insurance coverage or on high-deductible plans.
How to Get a Zepbound Prescription
Zepbound requires a prescription from a licensed physician, nurse practitioner, or physician assistant. You cannot buy it over the counter.
Your prescriber will check your BMI, weight-related health conditions, and medication history. They will also review the thyroid cancer contraindication and any personal or family history.
Telehealth platforms can prescribe Zepbound or compounded tirzepatide. You complete an intake form, submit lab work if required, and connect with a licensed provider. Many telehealth platforms prescribe in most US states and ship medication to your door.
SHED MD is the top-rated telehealth program on this site. Real physicians review every case. They prescribe in most US states and include ongoing monitoring with your membership.
Zepbound vs. Wegovy: A Quick Summary
| Factor | Zepbound | Wegovy |
|---|---|---|
| Active ingredient | Tirzepatide | Semaglutide |
| Mechanism | GIP + GLP-1 dual agonist | GLP-1 agonist only |
| Avg weight loss (trial) | 20.9% (SURMOUNT-1) | 15% (STEP-1) |
| Head-to-head (SURMOUNT-5) | 20.2% | 13.7% |
| List price (no insurance) | ~$1,060/mo | ~$1,350/mo |
| Manufacturer | Eli Lilly | Novo Nordisk |
Common Questions
How much does Zepbound cost per month?
With insurance and the Lilly savings card, Zepbound costs as low as $550/month for eligible patients with commercial insurance. Without insurance, it runs approximately $1,060/month for a single auto-injector pen. Compounded tirzepatide from telehealth providers costs $200 to $600/month depending on dose and provider.
How long does it take Zepbound to work?
Most people notice reduced appetite in the first 1 to 2 weeks. Measurable weight loss shows up by week 4. The SURMOUNT-1 trial ran 72 weeks to reach 20.9% average weight loss at the 15mg dose. Expect gradual, consistent progress rather than rapid early results.
Is Zepbound better than Wegovy?
In the SURMOUNT-5 head-to-head trial, Zepbound outperformed Wegovy. Average weight loss was 20.2% on Zepbound vs 13.7% on Wegovy. And 47% of Zepbound patients lost more than 25% of body weight, compared to 27% on Wegovy.
What is the difference between Zepbound and Mounjaro?
Same drug (tirzepatide), different FDA approval. Mounjaro is approved for type 2 diabetes. Zepbound is approved for chronic weight management in adults with obesity or overweight with a weight-related health condition. Insurance coverage differs. Zepbound is more likely to be covered for weight loss. Mounjaro typically requires a diabetes diagnosis.
Can I get Zepbound online?
Yes, through licensed telehealth providers. A physician or nurse practitioner must evaluate you and write a prescription. Platforms like SHED MD operate in most US states. Some prescribe branded Zepbound. Many prescribe compounded tirzepatide as a lower-cost alternative when the branded drug is on shortage.